Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

The latest health news covers the European Medicines Agency supporting Novo Nordisk’s drug for heart failure in obese ...

The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...